Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 over exp |
| Therapy | Anlotinib + Cisplatin + Nab-paclitaxel + Sintilimab |
| Indication/Tumor Type | lung sarcomatoid carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 over exp | lung sarcomatoid carcinoma | predicted - sensitive | Anlotinib + Cisplatin + Nab-paclitaxel + Sintilimab | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Anlotinib (AL-3818) and Sintilimab (IBI308) plus Platinol (cisplatin) and Abraxane (nab-paclitaxel) resulted in a partial response in a metastatic pulmonary sarcomatoid carcinoma patient with high CD274 (PD-L1) expression (IHC=70%), and the patient remained on Anlotinib (AL-3818) and Sintilimab (IBI308) maintenance therapy with sustained disease control for more than 1 year (PMID: 36267791). | 36267791 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36267791) | Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review. | Full reference... |